Topic: T Mu

A caller points out that CBS has been advertising "No Kings" merchandise on platforms like T-Mu and Amazon, suggesting corporate backing for the protest movement. The host links CBS to "Operation Mockingbird" and the CIA. The segment concludes with a high-energy endorsement of Methylene Blue as a tool for maintaining physical and mental stamina during the "information war."

The strategy of "vaccine chasing"—developing new boosters for every new variant—is compared to a dog chasing its tail. During the break, the host promotes "Down-N-Out," a natural sleep aid designed to be stronger than previous formulas to help maintain immune health during times of stress.

Dr. Richard Fleming explains that current COVID-19 vaccines circumvent the innate immune system and focus only on a single spike protein variant (Wuhan HU1). He argues this creates "vaccine chasing," where mass vaccination puts pressure on the virus to mutate into variants like Delta and Mu. Fleming asserts that the vaccines are failing to provide the promised protection.

Dr. Immanuel emphasizes the importance of using Budesonide inhalers and Z-Paks at the first sign of a "sniffle" to prevent hospitalization. She warns that the upcoming Lambda and Mu variants are being used to prepare the public for a new wave of illness that vaccines will not prevent. She concludes by promoting her book "Let America Live" and her ongoing fight against "diabolic" pharmaceutical interests.

Guest host Stu Peters discusses the emergence of the Mu variant and criticizes Anthony Fauci's track record. He provides an update on Australia, noting that the Premier of Victoria dismissed parliament and that the military is enforcing lockdowns in Sydney, while South Australia implements facial recognition tracking.

Dr. Alexander points to Israel's high infection rates as evidence that the vaccines have failed. He and Stu Peters discuss the "variant narrative" as a means to maintain fear and push for a lifetime subscription to booster shots, which they claim will lead to widespread antibody-dependent enhancement (ADE).